Avoid common mistakes on your manuscript.
Correction to: Applied Microbiology and Biotechnology (2020) 104:8231–8242
There is an error in the Introduction section of the original publication. The text “Two are against advanced melanoma, among which one was approved in the USA, Europe, and Australia based on a modified oncolytic herpes simplex virus (HSV) type 1 known as talimogene laherparepvec (T-VEC) and the other a reovirus sold under the name Rigvir commercialized in Latvia, Estonia, Poland, and Belarus (Alberts et al. 2016; Harrington et al. 2015).” should be replaced by:
“Two are against advanced melanoma, among which one was approved in the USA, Europe, and Australia based on a modified oncolytic herpes simplex virus (HSV) type 1 known as talimogene laherparepvec (T-VEC) and the other an ECHO-7 virus sold under the name Rigvir and approved in Latvia, Georgia, Armenia and Uzbekistan (Alberts et al. 2016; Doniņa et al. 2015; Alberts et al. 2018).”
References
Alberts P, Olmane E, Brokāne L, Krastiņa Z, Romanovska M, Kupčs K, Isajevs S, Proboka G, Erdmanis R, Nazarovs J, Venskus D (2016) Long-term treatment with the oncolytic ECHO-7 virus Rigvir of a melanoma stage IV M1c patient, a small cell lung cancer stage IIIA patient, and a histiocytic sarcoma stage IV patient-three case reports. Acta Pathol Microbiol Immunol Scand 124(10):896–904. https://doi.org/10.1111/apm.12576
Alberts P, Tilgase A, Rasa A, Bandere K, Venskus D (2018) The advent of oncolytic virotherapy in oncology: the Rigvir® story. Eur J Pharmacol 837:117–126. https://doi.org/10.1016/j.ejphar.2018.08.042
Doniņa S, Strēle I, Proboka G, Auziņš J, Alberts P, Jonsson B, Venskus D, Muceniece A (2015) Adapted ECHO-7 virus Rigvir immunotherapy (oncolytic virotherapy) prolongs survival in melanoma patients after surgical excision of the tumour in a retrospective study. Melanoma Res 25(5):421–426. https://doi.org/10.1097/CMR.0000000000000180
Author information
Authors and Affiliations
Corresponding authors
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
The online version of the original article can be found at https://doi.org/10.1007/s00253-020-10802-w
Rights and permissions
About this article
Cite this article
Hu, PY., Fan, XM., Zhang, YN. et al. Correction to: The limiting factors of oncolytic virus immunotherapy and the approaches to overcome them. Appl Microbiol Biotechnol 105, 5257 (2021). https://doi.org/10.1007/s00253-021-11335-6
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00253-021-11335-6